Determine the necessary mass, volume, or concentration for preparing a solution.
KIF18A-IN-6 - ≥98% , CAS No.2914879-10-8
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity
In Vitro
KIF18A-IN-6 (Compound 134; 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCC-15, JIMT-1 and NIH-OVCAR3 Concentration: Incubation Time: 7 days Result: Inhibited cell viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM against JIMT-1, HCC-15 and NIH-OVCAR3 cells, respectively.
In Vivo
KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) inhibits HCC15 and OVCAR3 tumor growth in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID Beige mice, HCC15 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice a day for 1 month Result: Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively. Animal Model: Balb/C nude mice, OVCAR3 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice or once a day for 1 month Result: Completely inhibited tumor growth (over 100%) over 30 mg/kg.
Form:Solid
IC50& Target:IC50: 0.016 μM (KIF18A microtubule-dependent ATPase activity)
Specifications
Specifications & Purity
≥98%
Biochemical and Physiological Mechanisms
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Purity
≥98%
Names and Identifiers
| Molecular Weight | 559.74 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 125 mg/mL (223.32 mM; Need ultrasonic) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.